75 results on '"Devoe, Craig"'
Search Results
2. AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.
3. DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
4. Abstract C092: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile lymph node targeted mutant KRAS vaccine
5. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
6. Table S3 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
7. Table S1 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
8. Table S3 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
9. Table S2 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
10. Data from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
11. Supplemental Figures from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
12. Table S5 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
13. Data from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
14. Supplemental Table Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
15. Table S2 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
16. Table S5 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
17. Table S4 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
18. Supplemental Figures from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
19. Table S1 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
20. Supplemental Figure Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
21. Supplemental Table Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
22. Supplemental Figure Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
23. Table S4 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
24. Supplementary Tables 1-2 and Supplementary Figures 1-2 from Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
25. Supplementary Tables 1-2 and Supplementary Figures 1-2 from Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
26. Supplemental Tables and Figures from Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
27. Supplemental Tables and Figures from Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
28. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
29. Inpatient utilization of immune checkpoint inhibitors and clinical outcomes
30. First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.
31. The Amyloidoses
32. Hematologic Evaluation
33. CTNI-45. RESPONSE EVALUATION OF AR-67 FROM A PHASE-2 RECURRENT GLIOBLASTOMA TRIAL BY ARTIFICIAL INTELLIGENCE ASSISTED TUMOR VOLUMETRIC ESTIMATION: COMPARISON WITH THE SUM OF THE PERPENDICULAR DIAMETERS PRODUCT
34. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients
35. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant
36. Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer
37. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
38. Association of TP53 mutation status and GATA6 amplification with clinical outcome of pancreatic cancer.
39. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
40. Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
41. ACTR-40. PHASE 2 SAFETY AND EFFICACY OF AR-67 (7-T-BUTYLDIMETHYLSILTYL-10-HYDROXYCAMPTOTHECIN) IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMA
42. Using a geographic and interdisciplinary strategy to improve patient care outcomes.
43. Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
44. Evaluation of prognostic factors after induction therapy in AML.
45. A retrospective review of nutritional status and immunotherapy in lung cancer.
46. Evaluation of Prognostic Factors after Induction Chemotherapy for Acute Myeloid Leukemia
47. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
48. Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
49. Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
50. Genomic Profiling of Small-Bowel Adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.